The purpose of this study is to establish the potential benefits, safety, and tolerability of AB-2004 in participants with irritability associated with autism spectrum disorder.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Enrollment
156
Harmonex Neuroscience Research
Dothan, Alabama, United States
The mean change in the ABC-I score (Irritability) from Baseline to Week 8 for AB-2004
Time frame: From baseline to Week 8 visit
The mean change in the Clinical Global Impression-Severity (CGI-S) from Baseline to Week 8 for AB-2004 High Dose and AB-2004 Low Dose
Time frame: From baseline to Week 8 visit
Number of participants who reported treatment emergent adverse events (TEAEs)
Time frame: From baseline to Week 8 visit
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Southwestern Autism Research and Resource Center
Phoenix, Arizona, United States
University of Arizona
Tucson, Arizona, United States
Cortica Marin
San Rafael, California, United States
Cortica Westlake
Westlake Village, California, United States
IMMUNOe Research Centers
Centennial, Colorado, United States
Yale University
New Haven, Connecticut, United States
CNS Solutions
Jacksonville, Florida, United States
CNS Solutions
Orlando, Florida, United States
University of South Florida
Tampa, Florida, United States
...and 14 more locations